Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting

Share Article

Bernstein Liebhard LLP is representing numerous plaintiffs who have filed Risperdal lawsuits in the Pennsylvania litigation, all of whom allegedly developed gynecomastia (male breast growth) due to their use of the antipsychotic medication.

Free Case Review
We are looking forward to this meeting, as it will provide important updates relevant to our clients’ claims, especially as it comes just weeks after the proceeding concluded its first two bellwether trials involving gynecomastia allegations.

The Pennsylvania Court overseeing a mass tort litigation housing hundreds of Risperdal lawsuits ( ) has scheduled a meeting for April 13th, 2015. According to the calendar for the Philadelphia Court of Common Pleas, the meeting will commence at 9:30 a.m. in Court Room 206, City Hall. Court records indicate that the proceeding will address the progress of product liability claims filed on behalf of Risperdal users who experienced gynecomastia (male breast growth) and other complications allegedly related to treatment with the antipsychotic drug. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is representing numerous clients in this mass tort who allegedly developed gynecomastia due to their use of Risperdal. We are looking forward to this meeting, as it will provide important updates relevant to our clients’ claims, especially as it comes just weeks after the proceeding concluded its first two bellwether trials involving gynecomastia allegations,” said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide Risperdal lawsuit consultations to men and boys who allegedly experienced excessive breast growth due to their use of the medication.

Risperdal Litigation
Court documents indicate that just over 1,300 Risperdal lawsuits have been filed in the mass tort program underway in Philadelphia. All of the gynecomastia cases pending in the proceeding accuse Johnson & Johnson and its Janssen Pharmaceuticals unit of concealing the association between the medication and male breast growth, and of failing to provide doctors and patients with adequate warnings about these risks. The lawsuits also allege that the companies improperly marketed Risperdal for off-label uses, including pediatric indications that did not receive regulatory approval until 2006.

According to court records, the litigation recently concluded its first two bellwether trials involving Risperdal and gynecomastia. The first trial ended on February 24th, with the jury awarding $2.5 million to an autistic man who experienced excessive breast growth after taking Risperdal as a child. (Case No. A-196444) The second trial concluded on March 20th, with the jury finding that Johnson & Johnson and Janssen’s warnings about male breast growth were inadequate. However, the plaintiff was not awarded any monetary damages because the panel concluded that he had not proven that Risperdal caused his condition. (Case No. 130301803)

Bernstein Liebhard LLP notes that bellwether trials are intended to act as test cases in large, complex litigations, and often provide insight into how juries might rule in similar cases. Court documents indicate that the bellwether trial program will continue in the Risperdal mass tort, with another gynecomastia trial set to get underway in Philadelphia on May 11th.

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website